Andrew J Innes
Overview
Explore the profile of Andrew J Innes including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
1212
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mullish B, Innes A, Roberts L, Anim-Burton S, Webber L, Johnson N, et al.
BMJ Open
. 2025 Jan;
14(12):e093120.
PMID: 39773995
Introduction: Lower diversity of the gut microbiome prior to allogeneic haematopoietic cell transplantation (HCT) correlates with reduced survival after the intervention. Most patients undergoing HCT for a haematological malignancy have...
2.
Innes A, Hayden C, Orovboni V, Claudiani S, Fernando F, Khan A, et al.
Leukemia
. 2024 Sep;
38(11):2443-2455.
PMID: 39300220
Asciminib is a potent and selective inhibitor of BCR::ABL1, with potential to avoid toxicity resulting from off-target kinase inhibition. Forty-nine patients treated with asciminib under a managed access program in...
3.
Fernando F, Andres M, Claudiani S, Kermani N, Ceccarelli G, Innes A, et al.
Cardiooncology
. 2024 Jul;
10(1):42.
PMID: 39010172
Background: The therapeutic landscape of chronic myeloid leukaemia (CML) has been transformed by tyrosine kinase inhibitors (TKI). Nilotinib, showed higher rates of major molecular response than imatinib, however associated with...
4.
Herranz N, Gallage S, Mellone M, Wuestefeld T, Klotz S, Hanley C, et al.
Nat Cell Biol
. 2024 May;
26(6):1019.
PMID: 38778130
No abstract available.
5.
Ng H, Robinson M, May P, Innes A, Hiemeyer C, Feldhahn N
Br J Haematol
. 2024 Jan;
204(3):945-958.
PMID: 38296260
EVI1 expression is associated with poor prognosis in myeloid leukaemia, which can result from Chr.3q alterations that juxtapose enhancers to induce EVI1 expression via long-range chromatin interactions. More often, however,...
6.
Rampotas A, Carter-Brzezinski L, Somervaille T, Forryan J, Panitsas F, Harrison C, et al.
Blood
. 2023 Nov;
143(2):178-182.
PMID: 37963262
Nonmelanoma skin cancers (NMSCs) in ruxolitinib-treated patients with myeloproliferative neoplasms behave aggressively, with adverse features and high recurrence. In our cohort, mortality from metastatic NMSC exceeded that from myelofibrosis. Vigilant...
7.
May P, Reid A, Robinson M, Khorashad J, Milojkovic D, Claudiani S, et al.
BMC Med Genomics
. 2023 Jul;
16(1):172.
PMID: 37496024
Background: Chronic myeloid leukaemia (CML) is one of the most well characterised human malignancies. Most patients have a cytogenetically visible translocation between chromosomes 9 and 22 which generates the pathognomonic...
8.
Fernando F, Innes A, Claudiani S, Pryce A, Hayden C, Byrne J, et al.
Bone Marrow Transplant
. 2023 Apr;
58(7):826-828.
PMID: 37015970
No abstract available.
9.
Milojkovic D, Reynolds C, Munoz Sandoval D, Pieper F, Liu S, Pade C, et al.
Leukemia
. 2022 Dec;
37(1):244-247.
PMID: 36528708
No abstract available.
10.
Guerrero A, Innes A, Roux P, Buisman S, Jung J, Ortet L, et al.
Nat Aging
. 2022 Nov;
2:851-866.
PMID: 36438588
Cellular senescence is a stable type of cell cycle arrest triggered by different stresses. As such, senescence drives age-related diseases and curbs cellular replicative potential. Here, we show that 3-deazaadenosine...